## **Kluwer Patent Blog**

United Kingdom: Accord Healthcare Limited v. Medac Gesellschaft Für Klinische Spezialpräparate MBH, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2014-000011, 13 January 2016

Matthew Raynor (Bristows) · Tuesday, October 25th, 2016 · Landmark European Patent Cases

The Patents Court (Birss J) held that medac's patent EP (UK) 2 046 332 relating to the use of a formulation of methotrexate at a concentration of about 50 mg/ml for the treatment of individuals with inflammatory autoimmune diseases such as rheumatoid arthritis (RA) by subcutaneous injection, was obvious over one of the prior art citations. The Court also considered the possibility of a squeeze between plausibility and inventive step Finally, the Judge stated that arguments of lack of inventive step over the common general knowledge alone should be approached with a degree of skepticism.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

## Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer



This entry was posted on Tuesday, October 25th, 2016 at 11:06 am and is filed under United Kingdom You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.